Andere Kunden interessierten sich auch für
![Frontiers in Clinical Drug Research - CNS and Neurological Disorders]( "Frontiers in Clinical Drug Research - CNS and Neurological Disorders")
Frontiers in Clinical Drug Research - CNS and Neurological Disorders122,99 €![Frontiers in Clinical Drug Research - CNS and Neurological Disorders, Volume 4]( "Frontiers in Clinical Drug Research - CNS and Neurological Disorders, Volume 4")
Frontiers in Clinical Drug Research - CNS and Neurological Disorders, Volume 4125,99 €![Frontiers in Clinical Drug Research - CNS and Neurological Disorders]( "Frontiers in Clinical Drug Research - CNS and Neurological Disorders")
Frontiers in Clinical Drug Research - CNS and Neurological Disorders86,99 €![The Neurobiological Basis of Suicide]( "The Neurobiological Basis of Suicide")
The Neurobiological Basis of Suicide90,99 €![The Psychological Autopsy]( "The Psychological Autopsy")
The Psychological Autopsy68,99 €![Neuroscience Biomarkers and Biosignatures]( "Neuroscience Biomarkers and Biosignatures")
Neuroscience Biomarkers and Biosignatures48,99 €![Program Implementation in Preventive Trials]( "Program Implementation in Preventive Trials")
Program Implementation in Preventive Trials76,99 €
"The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description.